High dose cyclophosphamide with carboplatin: A tolerable regimen suitable for dose intensification in children with solid tumors

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 4, 1997, Pages 309-312

  Kreissman, Susan G ^a   Rackoff, Wayne ^a   Lee, Melissa ^a   Breitfeld, Philip P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Cyclophosphamide; G CSF; Solid tumor

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; SALVAGE THERAPY;

EID: 0030720939     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199707000-00008     Document Type: Article

References (20)

1. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-8.
2. Schwenn MR, Blattner SR, Lynch E, et al. HiC-COM: a 2 month intensive chemotherapy regimen for children with stage III and IV Burkitt’s lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991; 9: 133-8.
3. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-94.
4. Collins C, Mortimer J, Livingston RB, et al. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 1989; 63: 228-32.
5. West DC, Shamberger RC, Macklis RM, et al. Stage II Neuroblastoma over one year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents (MADDOC). J Clin Oncol 1993; 11: 84-90.
6. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children’s Cancer Group. Cancer 1994; 73: 1297-1301.
7. Friedman H, Krucher J, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992; 10: 249-56.
8. Kushner BH, O’Reilly RJ, LaQuaglia M, et al. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. Cancer 1990; 66: 1095-1100.
9. Housholder S, Rackoff W, Breitfeld P. A Case-Control retrospective study of the efficacy of granulocyte-colony stimulating factor in children with neuroblastoma. J Pediatr Hematol Oncol 1994; 16: 132-7.
10. Conover, WJ. Practical Nonparametric Statistics, second edition. New York: John Wiley and Sons Inc., 1980: 206-15.
11. Tepler S, Cannistra S, Smith I, et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive out patient high dose carboplatin and cyclophosphamide therapy. J Clin Oncol 1993; 11: 1583-91.
12. White L, McCowage G, Kannourakis G, et al. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 1994; 12: 522-31.
13. Cairo M, Shen W-P, Miser J, et al. A randomized trial of two doses of G-CSF (5.0 vs. 10.0 mcg/kg/d) following ifosfamide, carboplatin and etoposide chemotherapy in children with recurrent solid tumors: significant clinical activity but no improvement in hematopoietic recovery with increased dose of G-CSF. J Clin Oncol 1995; 14(suppl): 255.
14. Meresse V, Vassal G, Michon J, et al. Combined continuous infusion etoposide with high dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol 1993; 11: 630-7.
15. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-24.
16. Klingemann H, Shepard DE, Reece MJ, et al. Regimen related acute toxicities: pathophysiology, risk factors, clinical evaluation, and preventive strategies. Bone Marrow Transplant 1994; 14 (suppl 4): S14-18.
17. Ortega J, Donaldson S, Ivy SP, et al. Venoocclusive disease (VOD) of the liver following vincristine-actinomycin-D-cyclophosphamide (VAC) therapy for rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma (IRS) group. J Clin Oncol 1995; 14(suppl): 440.
18. Marina N, Shema S, Bowman LC, et al. Failure of Granulocytemacrophage stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 1994; 23: 328-34.
19. Tepler I, Elias L, Smith I, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-14.
20. Magni M, Shammah S, Schiro R, et al. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87: 1097-103.